Protein Kinase Inhibitors
Showing 1 - 25 of >10,000
Cancer Trial in Changsha (Protein Kinase Inhibitor)
Recruiting
- Cancer
- Protein Kinase Inhibitor
-
Changsha, Hunan, ChinaCentral South University
Jun 23, 2022
Protein Kinase Inhibitors, Other Protocol Specified Criteria, Lung Tumors Trial in Guangzhou (JYP0322)
Recruiting
- Protein Kinase Inhibitors
- +3 more
-
Guangzhou, Guangdong, ChinaSun Yat-Sen University Cancer Center
Nov 9, 2023
Cancer, High-grade Glioma Trial in Amsterdam (Sunitinib, vandetanib, Erlotinib)
Unknown status
- Cancer
- High-grade Glioma
- Sunitinib
- +2 more
-
Amsterdam, Noord-Holland, NetherlandsVU University Medical Center
Oct 6, 2020
NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in Worldwide (Furmonertinib)
Recruiting
- Non-Small Cell Lung Cancer
- +14 more
-
Glendale, California
- +12 more
Feb 2, 2023
Occurrence and Concentrations of Ibrutinib and Idelalisib
Completed
- Hematological Malignancies
- Blood samples for pharmacokinetics exploration
- +7 more
-
Toulouse, FranceCancer University Institute of Toulouse Oncopole
Dec 24, 2020
Kinase Inhibitors Based on Protein Phosphorylation Profiles in
Terminated
- Renal Cell Cancer
-
Amsterdam, Noord Holland, NetherlandsVU Medical Center
Nov 18, 2020
CML Trial in Ciudad Autonoma de Buenos Aire (Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment)
Recruiting
- CML
- Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
-
Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, ArgentinaFUNDALEU
Jun 29, 2023
Tyrosine Kinase Inhibitors on Liver Enzymes and Electrolytes
Active, not recruiting
- Patients Diagnosed as Chronic Meyloid Leukemia
- Tyrosine kinase Inhibitors (Imatinib & Nilotinib)
-
Assiut, EgyptAssiut University Hospital
Feb 19, 2022
Kidney Cancer Trial in Grenoble (CK2 and ATM inhibitors serine/ threonin Kinase combination, Sunitinib, Pazopanib)
Recruiting
- Kidney Cancer
- CK2 and ATM inhibitors serine/ threonin Kinase combination
- +3 more
-
Grenoble, FranceGrenoble Alps Hospital
Jan 16, 2020
Tyrosine Kinase Inhibitors, Chronic Myeloid Leukemia Trial in Poitiers (treatment of TKI in CML)
Not yet recruiting
- Tyrosine Kinase Inhibitors
- Chronic Myeloid Leukemia
- treatment of TKI in CML
-
Poitiers, FranceChu Poitiers
Feb 21, 2023
NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in United States (furmonertinib 240 mg, furmonertinib 160 mg, platinum-based chemo)
Recruiting
- Non-Small Cell Lung Cancer
- +13 more
- furmonertinib 240 mg
- +2 more
-
Yuma, Arizona
- +37 more
Dec 14, 2022
Cyclin-dependent Kinase 4/6 Inhibitors on Body Composition in
Recruiting
- Breast Cancer
- CT scans
- DEXA scan
-
Bronx, New YorkMontefiore Medical Center
Jan 6, 2023
Breast Cancer Stage IV Trial in Mansoura (comparing both arms as regard the objective response rate, toxicity profile, quality
Recruiting
- Breast Cancer Stage IV
- comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
-
Mansoura, Dakahlia, EgyptOncology center mansoura university
Jan 1, 2023
Idiopathic Inflammatory Myopathies Trial in Beijing (tofacitinib)
Recruiting
- Idiopathic Inflammatory Myopathies
-
Beijing, Beijing, ChinaDepartment of Rheumatology and Immunology, Peking University Peo
Oct 9, 2022
Carcinoma, Carcinoma, Renal Cell, Kidney Tumors Trial in Worldwide (Savolitinib, Sunitinib)
Active, not recruiting
- Carcinoma
- +7 more
-
La Jolla, California
- +58 more
Jan 13, 2023
Liver Transplant; Complications, Hepatocarcinoma, Recurrent Osteosarcoma Trial in Beijing (multi-kinase inhibitors in
Not yet recruiting
- Liver Transplant; Complications
- +3 more
- multi-kinase inhibitors in combination with bevacizumab
-
Beijing, Beijing, ChinaChinese Academy of Medical Sciences & Peking Union Medical Colle
Sep 11, 2023
Skin Health and Quality of Life in Patients Receiving
Not yet recruiting
- Lung Cancer
- +7 more
- EQ-5D-5L questionnaire
- +2 more
-
Roma, ItalyRoberto Iacovelli
May 17, 2023
Hepatocellular Carcinoma, Liver Tumors, Digestive System Tumors Trial in Chengdu (TACE combined with sorafenib and PD-1 mAb)
Recruiting
- Hepatocellular Carcinoma
- +7 more
- TACE combined with sorafenib and PD-1 mAb
-
Chengdu, Sichuan, ChinaSichuan Cancer Hospital and Research Institute
Sep 14, 2020
Janus Kinase Inhibitors Vs Tumor Necrosis Factor Inhibitors in
Not yet recruiting
- Rheumatoid Arthritis
- Observation
- (no location specified)
Oct 8, 2022
B-cell Malignancies Undergoing Treatment With Bruton Tyrosine
Not yet recruiting
- Chronic Lymphocytic Leukemia
- +4 more
- Non-Interventional Study
-
Rochester, MinnesotaMayo Clinic in Rochester
Nov 22, 2023
Non Small Cell Lung Cancer Trial in Mexico City (Metformin Hydrochloride, Placebo)
Recruiting
- Non Small Cell Lung Cancer
- Metformin Hydrochloride
- Placebo
-
Mexico City, MexicoInstituto Nacional de Cancerologia
Jul 21, 2022
Atrial Fibrillation, Supraventricular Arrhythmia, Ventricular Arrhythmias and Cardiac Arrest Trial in New Hyde Park (Medtronic
Recruiting
- Atrial Fibrillation
- +4 more
- Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)
-
New Hyde Park, New YorkNorthwell (Northshore University/Long Island Jewish Hospitals)
Dec 1, 2022
Polycystic Ovary Syndrome Trial (SGLT2 inhibitors combined with metformin, Placebo combined with metformin)
Not yet recruiting
- Polycystic Ovary Syndrome
- SGLT2 inhibitors combined with metformin
- Placebo combined with metformin
- (no location specified)
Jul 21, 2023
EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma, Stage IV NSCLC Trial in Winston-Salem (drug, biological,
Terminated
- EGFR Activating Mutation
- +2 more
- Chemotherapy
- +6 more
-
Winston-Salem, North CarolinaComprehensive Cancer Center of Wake Forest University
Jan 28, 2021